Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0821 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.0821 | 0.5 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.0821 | 0.5 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.0821 | 0.5 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0821 | 0.5 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.0821 | 0.5 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.0821 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.